The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys-Reference-Cited by-同舟云学术

The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys

Published:2014-04-27 Issue:10 Volume:16 Page:910-921
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Roy D.¹,Chadwick K. D.²,Tatarkiewicz K.¹,LaCerte C.¹,Bergholm A.-M.³,Brodie T.²,Mangipudy R. S.²,Parkes D.¹,Graziano M. J.²,Reilly T. P.²

Affiliation:

1. Nonclinical Drug Safety; Amylin LLC, a Wholly Owned Subsidiary of Bristol-Myers Squibb Company; San Diego CA USA

2. Drug Safety Evaluation, Research & Development; Bristol-Myers Squibb Company, New Brunswick and; Princeton NJ USA

3. Global Safety Assessment; AstraZeneca; Mölndal Sweden

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12294/fullpdf

Reference80 articles.

1. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes;Kolterman;J Clin Endocrinol Metab,2003

2. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro;Parkes;Metabolism,2001

3. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes;Egan;J Clin Endocrinol Metab,2002

4. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells;Fehmann;Endocrinology,1992

5. Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight;Gedulin;Endocrinology,2005

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incretin mimetics and acute pancreatitis: enemy or innocent bystander?;Current Opinion in Gastroenterology;2024-07-04

2. Advances in Drug Treatments for Companion Animal Obesity;Biology;2024-05-11

3. Saxagliptin protects against diabetic nephropathy by inhibiting caspase 3/PARP‑1‑dependent nephrocyte apoptosis;Experimental and Therapeutic Medicine;2021-07-14

4. Nonclinical safety and pharmacokinetics of Miglyol 812: A medium chain triglyceride in exenatide once weekly suspension;Journal of Applied Toxicology;2018-05-28

5. Saxagliptin for the treatment of diabetes - a focus on safety;Expert Opinion on Drug Safety;2016-03-21